Strategic groups in the biopharmaceutical industry: Implications for performance
Publication typeJournal article with impact factor
JournalDrug Discovery Today
Publication Begin page726
Publication End page730
MetadataShow full item record
AbstractThe biopharmaceutical industry is characterized by intense competition, high uncertainty, and strong dependence on scientific knowledge. We show that in order to succeed in this industry, firms need to be positioned along three strategic dimensions: the level of inter-firm R&D partnering, the level of diversification, and the size of the firm. Prior research has revealed that a firm's membership in so-called ‘strategic groups’ impacts strongly on its performance. This study analyzes strategic groups in the biopharmaceutical industry along the strategic dimensions listed. The performance of the groups differs significantly. The best performing groups are the ones that consist of large firms with a high level of in-house diversification across therapeutic areas and the medium-sized firms that pursue partnership with other companies.
Special Industries : Healthcare Management
- Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
- Authors: Wellenreuther R, Keppler D, Mumberg D, Ziegelbauer K, Lessl M
- Issue date: 2012 Nov
- Clusters in the biopharmaceutical industry: toward a new method of analysis.
- Authors: Erden Z, von Krogh G
- Issue date: 2011 May
- An audience with...Francis Collins. Interviewed by Asher Mullard.
- Authors: Collins F
- Issue date: 2011 Jan
- Drug discovery: new models for industry-academic partnerships.
- Authors: Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A
- Issue date: 2009 Jan
- Can emerging drug classes improve R&D productivity?
- Authors: Meier C, Cairns-Smith S, Schulze U
- Issue date: 2013 Jul